|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:dateCreated |
1990-3-15
|
|
pubmed:abstractText |
Treatment of patients with fibromyomata by Zoladex produces suppression of ovarian function. Receptor changes also occur in fibroids of women treated with Zoladex. The concentration of oestradiol receptors is significantly higher, whilst that of epidermal growth factor and progesterone is significantly lower.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
0301-0163
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
32 Suppl 1
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
154-6
|
|
pubmed:dateRevised |
2009-11-19
|
|
pubmed:meshHeading |
pubmed-meshheading:2533146-Buserelin,
pubmed-meshheading:2533146-Female,
pubmed-meshheading:2533146-Goserelin,
pubmed-meshheading:2533146-Humans,
pubmed-meshheading:2533146-Leiomyoma,
pubmed-meshheading:2533146-Receptor, Epidermal Growth Factor,
pubmed-meshheading:2533146-Receptors, Estradiol,
pubmed-meshheading:2533146-Receptors, Progesterone,
pubmed-meshheading:2533146-Uterine Neoplasms
|
|
pubmed:year |
1989
|
|
pubmed:articleTitle |
Effect of treatment with LHRH analogue Zoladex on binding of oestradiol, progesterone and epidermal growth factor to uterine fibromyomata.
|
|
pubmed:affiliation |
Department of Obstetrics and Gynaecology, University of Edinburgh, Centre for Reproductive Biology, UK.
|
|
pubmed:publicationType |
Journal Article
|
